Vical (VICL)
Vical Revenues: 11.46M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VICL Revenues Rankings
| Overall | 15th percentile | 3763 of 4431 |
| Sector | 35th percentile | 306 of 471 in Healthcare |
| Industry | 54th percentile | 60 of 132 in Biotechnology |
VICL Revenues Range, Past 5 Years
| Minimum | 0.375M | Sep 2007 |
| Maximum | 26.62M | Sep 2011 |
| Average | 3.754M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these VICL related companies
VICL News
@gotgame83 with u being a Physician, can you give me your take on $VICL. it looks very interesting 2 me. Thx
about 10 days ago by Bleedblue
about 10 days ago by Bleedblue
Approx. 1 out of every 6 ppl in the U S and an estimated 1 out of every 4 worldwide is infected by HSV-2 before age 50. $VICL could b cure!
about 10 days ago by Bleedblue
about 10 days ago by Bleedblue
RT $VICL stock to concider 4 us looking 4 next long maybe? could be ground braking. http://stks.co/3vnJ < any feed back?>
about 10 days ago by Bleedblue
about 10 days ago by Bleedblue
$VICL stock to concider 4 us looking 4 next long maybe? could be ground braking. http://stks.co/3vnD
about 10 days ago by Bleedblue
about 10 days ago by Bleedblue
Vical's CEO Presents at Bank of America Merrill Lynch Health Care Conference Call (Transcript)
May 16, 8:21PM Seeking Alpha
May 16, 8:21PM Seeking Alpha
$VICL forms bearish "Top Triangle" chart pattern. http://stks.co/3qVE
about 17 days ago by RecogniaEvents
about 17 days ago by RecogniaEvents
Listen to $VICL Q1 2012 earnings call - live at 12:00 PM, ondemand after - http://stks.co/3czY
about 30 days ago by earningscast
about 30 days ago by earningscast
$VICL The future looks great for Vical. Remaining long on this stock with revenues starting to skyrocket. http://stks.co/3cfI
about 30 days ago by megreedy
about 30 days ago by megreedy
Vical Reports First Quarter 2012 Financial Results and Progress in Key Development Programs
May 02, 6:30AM GlobeNewswire
May 02, 6:30AM GlobeNewswire
$VICL Vical coverage assumed with an Outperform at Credit Suisse Target $5.
about 37 days ago by maxicat
about 37 days ago by maxicat
Vical Announces News Release and Conference Call Schedule for First Quarter 2012 Financial Results http://stks.co/3Usb $VICL
about 37 days ago by VicalInc
about 37 days ago by VicalInc
Vical Announces News Release and Conference Call Schedule for First Quarter 2012 Financial Results
Apr 25, 6:30AM GlobeNewswire
Apr 25, 6:30AM GlobeNewswire
Vical & Astellas won Vaccine Industry Excellence Award; Best Vaccine Licensing Deal at World Vaccine Congress $VICL http://dcl.sr/16P
about 38 days ago by VicalInc
about 38 days ago by VicalInc
$VICL filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3Kmq
about 49 days ago by MarketBrief
about 49 days ago by MarketBrief
Astellas and Vical Advance Toward Phase 3 Trial of TransVax(TM) CMV Vaccine Triggering $10 Million Milestone P... http://stks.co/3Ave $VICL
about 60 days ago by VicalInc
about 60 days ago by VicalInc
Vical (VICL) Reports Development of Vaxfectin-Formulated DNA Vaccine Candidate
Mar 28, 6:57AM Street Insider
Mar 28, 6:57AM Street Insider
Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant
Mar 28, 6:40AM Benzinga
Mar 28, 6:40AM Benzinga
Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant http://stks.co/36v9 $VICL
about 65 days ago by VicalInc
about 65 days ago by VicalInc
$VICL forms bullish "Continuation Wedge" chart pattern. http://stks.co/2lrQ
about 84 days ago by RecogniaEvents
about 84 days ago by RecogniaEvents
U.S. Navy Advances Dengue DNA Vaccine Using Vical's Vaxfectin(R) Adjuvant http://stks.co/2fUa $VICL
about 88 days ago by VicalInc
about 88 days ago by VicalInc
Vical to Present at Upcoming Investor Conferences http://stks.co/2bh7 $VICL
about 93 days ago by VicalInc
about 93 days ago by VicalInc
Vical's CEO Hosts at Citi 2012 Global Health Care Conference (Transcript)
Feb 28, 8:58PM Seeking Alpha
Feb 28, 8:58PM Seeking Alpha
Vical to Present at Upcoming Investor Conferences http://stks.co/2MuC $VICL
about 109 days ago by VicalInc
about 109 days ago by VicalInc
Canaccord Genuity Maintains a 'Buy' on Vical (VICL); Still Attractive Risk/Reward
Feb 09, 11:17AM Street Insider
Feb 09, 11:17AM Street Insider
Vical Reports 2011 Financial Results and Progress in Key Development Programs
Feb 08, 6:30AM GlobeNewswire
Feb 08, 6:30AM GlobeNewswire
Vical Announces News Release and Conference Call Schedule for 2011 Financial Results
Feb 02, 6:30AM GlobeNewswire
Feb 02, 6:30AM GlobeNewswire
Vical Presents Case Study on Successful Design of Allovectin Phase 3 Melanoma Trial
Jan 30, 6:38AM Benzinga
Jan 30, 6:38AM Benzinga
Vical Presents Case Study on Successful Design of Allovectin(R) Phase 3 Melanoma Trial
Jan 30, 6:30AM GlobeNewswire
Jan 30, 6:30AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VICL | 2.80 | -0.12 | -4.11% | 250.77M |
| VIAS | 18.30 | -0.91 | -4.74% | 394.96M |
| VIA.B | 46.28 | -1.45 | -3.04% | 23.33B |
| VIA | 51.39 | -1.41 | -2.67% | 2.714B |
| VHI | 13.58 | -0.60 | -4.23% | 4.809B |
| VHC | 32.09 | -1.25 | -3.75% | 1.689B |
| VGZ | 3.10 | +0.21 | +7.27% | 206.64M |
| VGR | 16.44 | -0.16 | -0.96% | 1.319B |
| ULE | 21.83 | +0.18 | +0.83% | |
| ULBI | 4.11 | -0.12 | -2.84% | 73.43M |